Streetbeat News

Products Services

BABA

INTC

TSLA

TSM

XPEV

Cryptocurrencies like Bitcoin, Ethereum, and Dogecoin are experiencing a dip amid high selling pressure, with analysts suggesting Bitcoin won't see highs unless it breaks $69K. Tesla is shifting investor focus to its energy business amid an auto slowdown. ARK's Bitcoin ETF sees a record outflow, and Intel, XPeng stocks move lower. Alibaba announces a $4.8B stock repurchase, and TSMC suspends chip production due to a tremor in Taiwan. Tesla faces criticism and potential fourth session of losses, while Geely's Zeekr revives IPO plans.

Portfolio Pulse from Akanksha Bakshi

April 03, 2024 | 12:50 pm

VNDA

Vanda Pharmaceuticals Inc's (NASDAQ:VNDA) Fanapt (iloperidone) tablets received FDA approval for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval expands Fanapt's market, previously approved for schizophrenia treatment since 2009. Bipolar disorder affects approximately 2.8% of the U.S. adult population, with a significant portion classified as severe. The approval was based on a pivotal study showing statistically significant improvement in patients treated with Fanapt over placebo. Despite this positive development, Vanda's net product sales for 2023 decreased by 4% Y/Y, with sales of another major drug, Hetlioz, declining due to increased competition. VNDA shares surged 27.9% in premarket trading following the announcement.

Portfolio Pulse from Vandana Singh

April 03, 2024 | 12:48 pm

SRZN

Surrozen has published a study in 'Respiratory Research' showcasing the potential of its Wnt mimetic technologies in treating pulmonary fibrosis. This development could mark a significant step forward in the treatment of this condition, potentially impacting Surrozen's market position and future revenue streams.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:41 pm

VRNT

Verint has expanded its partnership with Webex by Cisco, integrating Verint Open Platform's Unified Data Hub into the Webex App Hub. This integration aims to enhance customer experience (CX) automation through the Webex Contact Center.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:37 pm

MLSS

Milestone Scientific has started selling its CompuFlo Epidural Disposables at PRC Alliance Pain Relief Center, which has 8 locations in central Florida. Dr. Bakshi reported a 100% success rate with Epidural Steroid Injection procedures during the evaluation period.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:35 pm

GNPX

Genprex is expanding its clinical trial sites for the Acclaim-3 clinical study, which tests Reqorsa Therapy in combination with Tecentriq for treating small cell lung cancer. This expansion is in collaboration with a large network of community-based oncology practices. The Acclaim-3 study has received support from the FDA in the form of Orphan Drug and Fast Track Designations.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:32 pm

SYRA

Syra Health announced that its 'Syrenity' research study protocol has been approved by the Institutional Review Board. This approval marks a significant milestone for the company, potentially advancing its position in health research and development.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:20 pm

EPD

Enterprise Product Partners (EPD) announced plans to construct a new natural gas processing plant, with an expected service start in Q2 2026. Additionally, EPD has commenced service on Mentone 3 and Leonidas, expanding its processing capabilities.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:20 pm

AMD

INTC

TSM

Intel Corp aims for $15B in foundry revenue by 2030, despite current challenges and competition from TSMC, which is expected to be 10x larger in foundry revenues. JPMorgan's Harlan Sur maintains an underweight rating on Intel with a $37 price target. Intel's transition to EUV technology and long-term margin targets remain key to its strategy, despite short-term headwinds including a downturn in stock performance, datacenter share loss to AMD, and muted traction in datacenter accelerator products.

Portfolio Pulse from Surbhi Jain

April 03, 2024 | 12:19 pm

BNGO

Bionano Genomics announced the publication of a study demonstrating that its Optical Genome Mapping (OGM) technology can identify genetic aberrations in sarcoma samples that could lead to improved diagnosis. These aberrations were missed by traditional cytogenetic methods. This discovery could enhance the accuracy of sarcoma diagnoses, potentially leading to better patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:14 pm